SBI Securities Co. Ltd. Has $436,000 Stake in Zoetis Inc. $ZTS

SBI Securities Co. Ltd. trimmed its stake in Zoetis Inc. (NYSE:ZTS) by 70.3% during the third quarter, HoldingsChannel.com reports. The fund owned 2,980 shares of the company’s stock after selling 7,061 shares during the quarter. SBI Securities Co. Ltd.’s holdings in Zoetis were worth $436,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in ZTS. Halbert Hargrove Global Advisors LLC raised its stake in shares of Zoetis by 496.6% in the third quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after acquiring an additional 144 shares during the last quarter. NewSquare Capital LLC increased its holdings in Zoetis by 69.1% during the 2nd quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares in the last quarter. Financial Consulate Inc. bought a new position in Zoetis in the 3rd quarter valued at $39,000. SJS Investment Consulting Inc. boosted its stake in Zoetis by 1,606.3% in the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock worth $40,000 after purchasing an additional 257 shares in the last quarter. Finally, TruNorth Capital Management LLC acquired a new position in Zoetis in the third quarter worth $42,000. 92.80% of the stock is owned by institutional investors.

Zoetis News Roundup

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Pelican Bay Capital Management increased its stake and is betting on Zoetis to benefit from the expanding pet care market — a vote of confidence from an institutional investor that can support the stock. Pelican Bay Capital Management Bets on Zoetis (ZTS) to Capitalize on Expanding Pet Care Market
• Positive Sentiment: The board declared a second‑quarter cash dividend of $0.53 per share (annualized yield ~1.7%; ex‑dividend Apr 20, payable Jun 2). The payout supports income investors and signals steady free cash flow. Zoetis Declares Second Quarter 2026 Dividend
• Positive Sentiment: Analyst coverage from Zacks highlights Zoetis as likely to beat upcoming earnings estimates and flags it as a momentum stock — positive near‑term catalyst if results meet expectations. Zoetis (ZTS) Expected to Beat Earnings Estimates: Should You Buy?
• Neutral Sentiment: Coverage pieces note the stock’s year‑to‑date underperformance versus the broader market, though analysts remain cautiously bullish — indicating upside is dependent on execution rather than sentiment alone. Do Wall Street Analysts Like Zoetis Stock?
• Neutral Sentiment: Market calendars note Zoetis is projected to report quarterly results this week — an event that could be a catalyst either way depending on beats or guidance. Zoetis (ZTS) Projected to Post Quarterly Earnings on Thursday
• Negative Sentiment: A valuation/analysis piece cautions that Zoetis’ 2026 outlook is tempered by softer pet clinic visits and increased regulatory scrutiny, which could pressure revenue growth and multiples if trends persist. Zoetis (ZTS) Valuation Check As 2026 Outlook Is Tempered On Softer Pet Visits And Regulatory Scrutiny

Wall Street Analyst Weigh In

ZTS has been the subject of several research reports. HSBC set a $140.00 price objective on shares of Zoetis in a research report on Wednesday, December 10th. JPMorgan Chase & Co. lowered their price target on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a research report on Monday, December 15th. Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Finally, Weiss Ratings cut Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, January 28th. Five analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Zoetis currently has a consensus rating of “Hold” and an average price target of $152.45.

Zoetis Trading Up 0.5%

NYSE:ZTS opened at $127.40 on Friday. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28. The business’s 50-day simple moving average is $123.96 and its 200-day simple moving average is $136.31. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $177.00. The stock has a market capitalization of $56.14 billion, a PE ratio of 21.45, a price-to-earnings-growth ratio of 2.20 and a beta of 0.96.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Stockholders of record on Monday, April 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 annualized dividend and a dividend yield of 1.7%. Zoetis’s dividend payout ratio is currently 35.69%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.